panitumumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
human origin 4955 339177-26-3

Description:

MoleculeDescription

Synonyms:

  • panitumumab
  • vectibix
  • ABX-EGF
Recombinant human monoclonal antibody that binds to and inhibits the function of the EPIDERMAL GROWTH FACTOR RECEPTOR. It is used in the treatment of EGFR-expressing metastatic colorectal cancer that expresses wild-type ras gene (see GENES, RAS).
  • Molecular weight:
  • Formula:
  • CLOGP:
  • LIPINSKI: None
  • HAC: None
  • HDO: None
  • TPSA:
  • ALOGS:
  • ROTB: None

Drug dosage:

None

ADMET properties:

None

Approvals:

DateAgencyCompanyOrphan
Dec. 3, 2007 EMA Amgen Europe B.V.
Sept. 27, 2006 FDA AMGEN

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 1116.22 27.82 238 10137 4758 63473889
Skin toxicity 642.58 27.82 150 10225 4564 63474083
Paronychia 617.83 27.82 150 10225 5415 63473232
Hypomagnesaemia 396.30 27.82 156 10219 28581 63450066
Dry skin 277.41 27.82 150 10225 56737 63421910
Neutropenia 251.04 27.82 216 10159 174789 63303858
Neuropathy peripheral 241.81 27.82 177 10198 113490 63365157
Rash 224.91 27.82 358 10017 560513 62918134
Skin fissures 208.06 27.82 76 10299 11312 63467335
Stomatitis 204.40 27.82 174 10201 138551 63340096
Rash pustular 200.43 27.82 66 10309 7216 63471431
Disease progression 195.33 27.82 161 10214 122597 63356050
Diarrhoea 185.86 27.82 378 9997 714988 62763659
Therapy partial responder 168.59 27.82 64 10311 10594 63468053
Skin disorder 122.30 27.82 70 10305 29437 63449210
Metastases to liver 119.72 27.82 64 10311 23575 63455072
Xerosis 106.47 27.82 26 10349 956 63477691
Neurotoxicity 103.26 27.82 52 10323 16938 63461709
Palmar-plantar erythrodysaesthesia syndrome 101.85 27.82 57 10318 22958 63455689
Peripheral sensory neuropathy 100.97 27.82 40 10335 7411 63471236
Mucosal inflammation 97.11 27.82 72 10303 46856 63431791
Polyneuropathy 92.63 27.82 46 10329 14543 63464104
Thrombocytopenia 90.09 27.82 117 10258 151040 63327607
Trichomegaly 88.94 27.82 15 10360 75 63478572
Skin reaction 88.92 27.82 45 10330 14804 63463843
Neutrophil count decreased 83.35 27.82 71 10304 56335 63422312
Drug ineffective 82.78 27.82 34 10341 1044731 62433916
Hypocalcaemia 75.52 27.82 53 10322 31660 63446987
Hypertrichosis 64.26 27.82 18 10357 1136 63477511
Acne 62.72 27.82 42 10333 23251 63455396
Malignant neoplasm progression 62.54 27.82 72 10303 82049 63396598
Colorectal cancer metastatic 60.25 27.82 15 10360 598 63478049
Blood magnesium decreased 59.22 27.82 33 10342 13165 63465482
Anaemia 58.37 27.82 140 10235 293290 63185357
Growth of eyelashes 57.66 27.82 12 10363 210 63478437
Hypokalaemia 55.11 27.82 76 10299 103728 63374919
Erythema 54.98 27.82 101 10274 175650 63302997
Arthralgia 52.88 27.82 14 10361 569696 62908951
Dehydration 52.19 27.82 98 10277 173256 63305391
Metastases to ovary 49.01 27.82 12 10363 446 63478201
Carcinoembryonic antigen increased 48.56 27.82 16 10359 1749 63476898
Decreased appetite 47.98 27.82 118 10257 250934 63227713
Conjunctivitis 47.75 27.82 34 10341 20762 63457885
Febrile neutropenia 47.46 27.82 76 10299 118373 63360274
Death 47.00 27.82 151 10224 374230 63104417
Leukopenia 46.23 27.82 60 10315 77230 63401417
Ileal perforation 44.07 27.82 11 10364 443 63478204
Dermatitis 41.90 27.82 29 10346 16929 63461718
Interstitial lung disease 41.70 27.82 51 10324 61857 63416790
Fall 39.62 27.82 8 10367 392326 63086321
Metastases to lung 39.23 27.82 25 10350 12725 63465922
Ileus 38.31 27.82 26 10349 14699 63463948
Abdominal discomfort 38.26 27.82 4 10371 320881 63157766
Headache 36.60 27.82 30 10345 633211 62845436
Gastrointestinal toxicity 33.76 27.82 19 10356 7722 63470925
Scab 33.71 27.82 19 10356 7744 63470903
Xeroderma 33.61 27.82 7 10368 123 63478524
Haematotoxicity 32.93 27.82 20 10355 9356 63469291
Pain of skin 31.36 27.82 21 10354 11613 63467034
Eye irritation 31.09 27.82 27 10348 21944 63456703
Nasopharyngitis 30.74 27.82 3 10372 254254 63224393
Pulmonary embolism 30.26 27.82 62 10313 116622 63362025
Peripheral swelling 29.99 27.82 4 10371 265938 63212709
Pain 28.90 27.82 48 10327 740580 62738067
Ascites 28.14 27.82 34 10341 40694 63437953

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 2086.20 24.86 506 16878 5683 34933864
Skin toxicity 1190.13 24.86 307 17077 4477 34935070
Paronychia 1103.15 24.86 270 17114 3135 34936412
Hypomagnesaemia 742.23 24.86 310 17074 21541 34918006
Rash 560.89 24.86 617 16767 222135 34717412
Rash pustular 436.45 24.86 145 17239 5263 34934284
Skin reaction 377.67 24.86 129 17255 5101 34934446
Stomatitis 346.18 24.86 232 17152 42282 34897265
Interstitial lung disease 292.11 24.86 249 17135 65033 34874514
Metastases to liver 275.80 24.86 135 17249 13528 34926019
Dry skin 252.75 24.86 170 17214 31117 34908430
Neuropathy peripheral 249.45 24.86 254 17130 83009 34856538
Disease progression 249.11 24.86 287 17097 107790 34831757
Neutropenia 246.65 24.86 344 17040 156434 34783113
Diarrhoea 242.67 24.86 570 16814 389342 34550205
Skin disorder 212.64 24.86 113 17271 13442 34926105
Therapy partial responder 196.97 24.86 96 17288 9520 34930027
Acne 195.75 24.86 100 17284 10966 34928581
Folliculitis 182.75 24.86 73 17311 4493 34935054
Skin fissures 166.14 24.86 71 17313 5188 34934359
Polyneuropathy 149.92 24.86 93 17291 14803 34924744
Conjunctivitis 144.03 24.86 78 17306 9627 34929920
Mucosal inflammation 130.55 24.86 126 17258 38496 34901051
Metastases to lung 116.71 24.86 67 17317 9253 34930294
Drug ineffective 103.91 24.86 49 17335 456702 34482845
Decreased appetite 102.27 24.86 243 17141 166149 34773398
Peripheral sensory neuropathy 102.16 24.86 55 17329 6705 34932842
Xerosis 94.78 24.86 27 17357 577 34938970
Palmar-plantar erythrodysaesthesia syndrome 93.73 24.86 73 17311 16722 34922825
Neurotoxicity 91.34 24.86 74 17310 17936 34921611
Carcinoembryonic antigen increased 90.66 24.86 27 17357 678 34938869
Thrombocytopenia 86.21 24.86 219 17165 156028 34783519
Hypocalcaemia 85.36 24.86 81 17303 24208 34915339
Neutrophil count decreased 78.27 24.86 111 17273 50993 34888554
Growth of eyelashes 75.97 24.86 16 17368 87 34939460
Erythema 69.49 24.86 143 17241 88637 34850910
Drug interaction 69.49 24.86 14 17370 225932 34713615
Blood magnesium decreased 69.44 24.86 42 17342 6381 34933166
Colorectal cancer metastatic 68.38 24.86 22 17362 718 34938829
Dermatitis 63.61 24.86 46 17338 9422 34930125
Headache 58.49 24.86 14 17370 200621 34738926
Arthralgia 57.87 24.86 8 17376 170033 34769514
Metastases to lymph nodes 56.55 24.86 33 17351 4695 34934852
Trichomegaly 54.77 24.86 10 17374 21 34939526
Pulmonary embolism 50.64 24.86 127 17257 89619 34849928
Ileus 46.82 24.86 49 17335 16450 34923097
Metastases to peritoneum 45.68 24.86 21 17363 1823 34937724
Hypertrichosis 45.32 24.86 14 17370 399 34939148
Gastrointestinal toxicity 43.54 24.86 23 17361 2696 34936851
Fall 42.60 24.86 24 17360 202861 34736686
Gene mutation 41.15 24.86 18 17366 1390 34938157
Blepharitis 40.70 24.86 18 17366 1427 34938120
Hepatectomy 40.18 24.86 9 17375 68 34939479
Metastases to pelvis 40.15 24.86 12 17372 305 34939242
Skin exfoliation 39.64 24.86 58 17326 27374 34912173
Perioral dermatitis 39.19 24.86 10 17374 138 34939409
Dehydration 38.62 24.86 147 17237 129822 34809725
Pustule 37.32 24.86 13 17371 544 34939003
Transient aphasia 37.25 24.86 12 17372 393 34939154
Intestinal obstruction 37.03 24.86 51 17333 22771 34916776
Skin lesion 37.03 24.86 50 17334 21911 34917636
Enterocolitis 36.56 24.86 31 17353 7995 34931552
Hypersensitivity 36.12 24.86 88 17296 60947 34878600
Somnolence 36.01 24.86 6 17378 111110 34828437
Febrile neutropenia 36.01 24.86 149 17235 136700 34802847
Mucocutaneous rash 35.85 24.86 7 17377 24 34939523
Carbohydrate antigen 19-9 increased 35.27 24.86 10 17374 210 34939337
Mucosal toxicity 33.58 24.86 10 17374 251 34939296
Dizziness 33.05 24.86 36 17348 218485 34721062
Device related infection 31.77 24.86 41 17343 17196 34922351
Product dose omission issue 31.76 24.86 10 17374 119701 34819846
Nail disorder 31.64 24.86 17 17367 2062 34937485
Overdose 31.63 24.86 4 17380 91055 34848492
Catheter site thrombosis 31.25 24.86 8 17376 112 34939435
Cough 31.15 24.86 18 17366 150122 34789425
Livedo reticularis 30.39 24.86 17 17367 2232 34937315
Hypokalaemia 30.34 24.86 80 17304 58134 34881413
Product use in unapproved indication 29.13 24.86 11 17373 117488 34822059
Diaphragmatic operation 28.91 24.86 6 17378 30 34939517
Confusional state 28.90 24.86 18 17366 144142 34795405
Toxicity to various agents 28.14 24.86 35 17349 200327 34739220
Cardiac failure congestive 28.10 24.86 4 17380 83266 34856281
Pain in extremity 27.95 24.86 14 17370 126499 34813048
Epidermal naevus syndrome 27.89 24.86 5 17379 9 34939538
Depression 27.82 24.86 7 17377 97091 34842456
Acne pustular 27.41 24.86 7 17377 97 34939450
Myocardial infarction 27.35 24.86 13 17371 121072 34818475
Hepatic lesion 27.15 24.86 19 17365 3693 34935854
Dermatitis infected 26.83 24.86 7 17377 106 34939441
Eyelash changes 26.64 24.86 5 17379 13 34939534
Ectropion 26.13 24.86 7 17377 118 34939429
Astringent therapy 25.41 24.86 5 17379 18 34939529
Insomnia 25.30 24.86 10 17374 103897 34835650

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Dermatitis acneiform 2964.75 23.55 670 23321 9323 79711074
Skin toxicity 1605.18 23.55 394 23597 7920 79712477
Paronychia 1446.50 23.55 358 23633 7450 79712947
Hypomagnesaemia 914.84 23.55 388 23603 46523 79673874
Rash pustular 570.34 23.55 188 23803 11123 79709274
Neuropathy peripheral 535.11 23.55 397 23594 140908 79579489
Rash 509.07 23.55 738 23253 577620 79142777
Stomatitis 460.81 23.55 369 23622 146388 79574009
Dry skin 456.19 23.55 273 23718 67722 79652675
Disease progression 454.22 23.55 403 23588 183959 79536438
Neutropenia 442.46 23.55 486 23505 287224 79433173
Therapy partial responder 389.52 23.55 159 23832 17238 79703159
Metastases to liver 387.47 23.55 183 23808 28131 79692266
Interstitial lung disease 363.63 23.55 288 23703 112312 79608085
Diarrhoea 342.87 23.55 789 23202 879700 78840697
Skin fissures 301.25 23.55 122 23869 12951 79707446
Skin reaction 289.98 23.55 126 23865 15942 79704455
Skin disorder 279.96 23.55 156 23835 33787 79686610
Polyneuropathy 261.25 23.55 133 23858 24018 79696379
Acne 227.03 23.55 126 23865 27064 79693333
Thrombocytopenia 199.85 23.55 316 23675 264943 79455454
Palmar-plantar erythrodysaesthesia syndrome 196.31 23.55 123 23868 33011 79687386
Mucosal inflammation 195.19 23.55 170 23821 75410 79644987
Neurotoxicity 175.94 23.55 114 23877 32404 79687993
Metastases to lung 170.57 23.55 91 23900 18072 79702325
Peripheral sensory neuropathy 165.30 23.55 80 23911 12953 79707444
Neutrophil count decreased 152.99 23.55 164 23827 93795 79626602
Conjunctivitis 151.15 23.55 95 23896 25620 79694777
Decreased appetite 136.55 23.55 311 23680 342107 79378290
Hypocalcaemia 128.24 23.55 112 23879 49812 79670585
Trichomegaly 123.37 23.55 23 23968 109 79720288
Drug ineffective 123.35 23.55 88 23903 1080825 78639572
Xerosis 120.75 23.55 34 23957 1172 79719225
Carcinoembryonic antigen increased 116.45 23.55 38 23953 2171 79718226
Arthralgia 109.47 23.55 20 23971 571783 79148614
Hypertrichosis 105.39 23.55 31 23960 1251 79719146
Colorectal cancer metastatic 102.06 23.55 30 23961 1208 79719189
Headache 98.41 23.55 37 23954 653735 79066662
Dermatitis 96.68 23.55 67 23924 21254 79699143
Growth of eyelashes 90.60 23.55 19 23972 179 79720218
Erythema 81.40 23.55 196 23795 223094 79497303
Drug interaction 76.28 23.55 16 23975 415167 79305230
Fall 76.02 23.55 26 23965 487603 79232794
Gene mutation 72.09 23.55 28 23963 2658 79717739
Ileus 71.74 23.55 61 23930 26150 79694247
Metastases to lymph nodes 70.25 23.55 42 23949 10355 79710042
Leukopenia 66.62 23.55 123 23868 116390 79604007
Pain 63.57 23.55 71 23920 703731 79016666
Metastases to peritoneum 62.04 23.55 29 23962 4343 79716054
Febrile neutropenia 59.15 23.55 178 23813 230821 79489576
Hypokalaemia 57.41 23.55 131 23860 143909 79576488
Peripheral swelling 57.08 23.55 7 23984 269610 79450787
Xeroderma 56.17 23.55 14 23977 298 79720099
Death 55.72 23.55 325 23666 566189 79154208
Gastrointestinal toxicity 55.41 23.55 33 23958 8076 79712321
Blood magnesium decreased 54.80 23.55 43 23948 16469 79703928
Pulmonary embolism 52.43 23.55 141 23850 171513 79548884
Blepharitis 51.49 23.55 23 23968 3101 79717296
Nasopharyngitis 50.43 23.55 8 23983 253873 79466524
Skin lesion 49.49 23.55 62 23929 41782 79678615
Pain in extremity 49.36 23.55 24 23967 364514 79355883
Folliculitis 48.65 23.55 71 23920 55309 79665088
Mucocutaneous rash 48.04 23.55 9 23982 44 79720353
Malignant neoplasm progression 48.03 23.55 118 23873 135872 79584525
Depression 47.46 23.55 5 23986 216785 79503612
Scab 47.40 23.55 33 23958 10539 79709858
Ectropion 47.12 23.55 13 23978 415 79719982
Pustule 46.98 23.55 19 23972 2006 79718391
Intestinal obstruction 46.56 23.55 61 23930 42959 79677438
Product dose omission issue 46.54 23.55 9 23982 247528 79472869
Hepatectomy 46.30 23.55 11 23980 190 79720207
Confusional state 46.08 23.55 19 23972 317978 79402419
Carbohydrate antigen 19-9 increased 46.06 23.55 13 23978 452 79719945
Skin exfoliation 46.04 23.55 69 23922 55031 79665366
Neoplasm progression 45.02 23.55 66 23925 51616 79668781
Dizziness 44.38 23.55 56 23935 526385 79194012
Cough 42.73 23.55 29 23962 366760 79353637
Abdominal discomfort 41.46 23.55 12 23979 250715 79469682
Transient aphasia 41.19 23.55 12 23979 468 79719929
Musculoskeletal stiffness 41.11 23.55 3 23988 175005 79545392
Haematotoxicity 40.19 23.55 35 23956 15484 79704913
Hepatic lesion 39.10 23.55 25 23966 6934 79713463
Mucosal toxicity 38.55 23.55 12 23979 588 79719809
Somnolence 38.49 23.55 12 23979 238969 79481428
Swelling 38.44 23.55 9 23982 216702 79503695
Device related infection 37.69 23.55 49 23942 34245 79686152
Asthenia 37.07 23.55 272 23719 511417 79208980
Dermatitis infected 37.04 23.55 10 23981 294 79720103
Product use issue 36.66 23.55 9 23982 209813 79510584
Toxicity to various agents 36.39 23.55 44 23947 421496 79298901
Drug intolerance 36.33 23.55 17 23974 264102 79456295
Ileal perforation 35.95 23.55 13 23978 1012 79719385
Drug hypersensitivity 35.66 23.55 23 23968 298893 79421504
Overdose 33.98 23.55 7 23984 184199 79536198
Papule 32.92 23.55 23 23968 7384 79713013
Therapeutic product effect decreased 32.90 23.55 5 23986 163858 79556539
Hyperammonaemia 32.80 23.55 27 23964 11066 79709331
Eczema impetiginous 32.26 23.55 6 23985 28 79720369
Weight increased 32.20 23.55 22 23969 277364 79443033
Diaphragmatic operation 31.91 23.55 6 23985 30 79720367
Cardiac failure congestive 31.90 23.55 3 23988 142399 79577998
Livedo reticularis 31.48 23.55 18 23973 4085 79716312
Thrombocytopenic purpura 30.83 23.55 15 23976 2454 79717943
Insomnia 30.44 23.55 18 23973 245152 79475245
Epidermal naevus syndrome 30.40 23.55 5 23986 9 79720388
Ascites 30.39 23.55 69 23922 75493 79644904
Perioral dermatitis 30.36 23.55 9 23982 373 79720024
Anaemia 30.19 23.55 233 23758 444782 79275615
Colon cancer metastatic 29.51 23.55 14 23977 2167 79718230
Metastases to pelvis 29.36 23.55 10 23981 652 79719745
IgA nephropathy 29.09 23.55 13 23978 1755 79718642
Product use in unapproved indication 28.86 23.55 20 23971 250339 79470058
Subileus 28.56 23.55 19 23972 5635 79714762
Metastasis 27.44 23.55 20 23971 6860 79713537
Dysgeusia 27.33 23.55 56 23935 57121 79663276
Nail disorder 27.26 23.55 25 23966 11827 79708570
Anxiety 27.16 23.55 21 23970 248491 79471906
Contusion 26.73 23.55 6 23985 148770 79571627
Metastases to ovary 26.59 23.55 8 23983 349 79720048
Enterocolitis 26.57 23.55 27 23964 14485 79705912
Bronchitis 26.19 23.55 4 23987 130640 79589757
Astringent therapy 25.97 23.55 5 23986 29 79720368
Lower respiratory tract infection 25.81 23.55 4 23987 129216 79591181
Blood pressure increased 25.56 23.55 16 23975 211344 79509053
Urinoma 25.42 23.55 7 23984 222 79720175
Drug effective for unapproved indication 25.20 23.55 18 23973 5983 79714414
Eye irritation 25.02 23.55 31 23960 20650 79699747
Dehydration 24.04 23.55 142 23849 248045 79472352
Feeling abnormal 23.88 23.55 9 23982 159190 79561207

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC L01FE02 ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
ANTINEOPLASTIC AGENTS
MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES
EGFR (Epidermal Growth Factor Receptor) inhibitors
FDA CS M0001357 Antibodies, Monoclonal
FDA MoA N0000020010 HER1 Antagonists
MeSH PA D000970 Antineoplastic Agents
MeSH PA D000074322 Antineoplastic Agents, Immunological
FDA EPC N0000175664 Epidermal Growth Factor Receptor Antagonist

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Secondary malignant neoplasm of colon indication 94260004




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Epidermal growth factor receptor Kinase AGONIST Kd 10.30 IUPHAR DRUG LABEL

External reference:

IDSource
D05350 KEGG_DRUG
4025701 VUID
N0000179714 NUI
4025701 VANDF
CHEMBL1201827 ChEMBL_ID
6883 IUPHAR_LIGAND_ID
DB01269 DRUGBANK_ID
263034 RXNORM
22205 MMSL
88497 MMSL
d05879 MMSL
011743 NDDF
423259008 SNOMEDCT_US
424401006 SNOMEDCT_US
C0879427 UMLSCUI
D000077544 MESH_DESCRIPTOR_UI
8499 INN_ID
6A901E312A UNII

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-954 SOLUTION 100 mg INTRAVENOUS BLA 28 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-954 SOLUTION 100 mg INTRAVENOUS BLA 28 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-954 SOLUTION 100 mg INTRAVENOUS BLA 28 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-956 SOLUTION 400 mg INTRAVENOUS BLA 28 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-956 SOLUTION 400 mg INTRAVENOUS BLA 28 sections
Vectibix HUMAN PRESCRIPTION DRUG LABEL 1 55513-956 SOLUTION 400 mg INTRAVENOUS BLA 28 sections